سوق فرط شحميات الدم العالمي - اتجاهات الصناعة والتوقعات حتى عام 2029

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF GLOBAL HYPERLIPIDEMIA MARKET

1.4 CURRENCY AND PRICING

1.5 LIMITATION

1.6 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 KEY TAKEAWAYS

2.2 ARRIVING AT THE GLOBAL HYPERLIPIDEMIA MARKET SIZE

2.2.1 VENDOR POSITIONING GRID

2.2.2 TECHNOLOGY LIFE LINE CURVE

2.2.3 TRIPOD DATA VALIDATION MODEL

2.2.4 MARKET GUIDE

2.2.5 MULTIVARIATE MODELLING

2.2.6 TOP TO BOTTOM ANALYSIS

2.2.7 CHALLENGE MATRIX

2.2.8 APPLICATION COVERAGE GRID

2.2.9 STANDARDS OF MEASUREMENT

2.2.10 VENDOR SHARE ANALYSIS

2.2.11 EPIDEMIOLOGY BASED MODEL

2.2.12 DATA POINTS FROM KEY PRIMARY INTERVIEWS

2.2.13 DATA POINTS FROM KEY SECONDARY DATABASES

2.3 GLOBAL HYPERLIPIDEMIA MARKET: RESEARCH SNAPSHOT

2.4 ASSUMPTIONS

3 MARKET OVERVIEW

3.1 DRIVERS

3.2 RESTRAINTS

3.3 OPPORTUNITIES

3.4 CHALLENGES

4 EXECUTIVE SUMMARY

5 PREMIUM INSIGHTS

5.1 PESTEL ANALYSIS

5.2 PORTER’S FIVE FORCES MODEL

6 INDUSTRY INSIGHTS

6.1 MICRO AND MACRO ECONOMIC FACTORS

6.2 PENETRATION AND GROWTH PROSPECT MAPPING

6.3 KEY PRICING STRATEGIES

6.4 INTERVIEWS WITH SPECIALIST

6.5 ANALYIS AND RECOMMENDATION

7 INTELLECTUAL PROPERTY (IP) PORTFOLIO

7.1 PATENT QUALITY AND STRENGTH

7.2 PATENT FAMILIES

7.3 LICENSING AND COLLABORATIONS

7.4 COMPETITIVE LANDSCAPE

7.5 IP STRATEGY AND MANAGEMENT

7.6 OTHER

8 COST ANALYSIS BREAKDOWN

9 TECHNONLOGY ROADMAP

10 INNOVATION TRACKER AND STRATEGIC ANALYSIS

10.1 MAJOR DEALS AND STRATEGIC ALLIANCES ANALYSIS

10.1.1 JOINT VENTURES

10.1.2 MERGERS AND ACQUISITIONS

10.1.3 LICENSING AND PARTNERSHIP

10.1.4 TECHNOLOGY COLLABORATIONS

10.1.5 STRATEGIC DIVESTMENTS

10.2 NUMBER OF PRODUCTS IN DEVELOPMENT

10.3 STAGE OF DEVELOPMENT

10.4 TIMELINES AND MILESTONES

10.5 INNOVATION STRATEGIES AND METHODOLOGIES

10.6 RISK ASSESSMENT AND MITIGATION

10.7 MERGERS AND ACQUISITIONS

10.8 FUTURE OUTLOOK

11 EPIDEMIOLOGY

11.1 INCIDENCE OF ALL BY GENDER

11.2 TREATMENT RATE

11.3 MORTALITY RATE

11.4 DRUG ADHERENCE AND THERAPY SWITCH MODEL

11.5 PATIENT TREATMENT SUCCESS RATES

12 REGULATORY COMPLIANCE

12.1 REGULATORY AUTHORITIES

12.2 REGULATORY CLASSIFICATIONS

12.2.1 CLASS I

12.2.2 CLASS II

12.2.3 CLASS III

12.3 REGULATORY SUBMISSIONS

12.4 INTERNATIONAL HARMONIZATION

12.5 COMPLIANCE AND QUALITY MANAGEMENT SYSTEMS

12.6 REGULATORY CHALLENGES AND STRATEGIES

13 PIPELINE ANALYSIS

13.1 CLINICAL TRIALS AND PHASE ANALYSIS

13.2 DRUG THERAPY PIPELINE

13.3 PHASE III CANDIDATES

13.4 PHASE II CANDIDATES

13.5 PHASE I CANDIDATES

13.6 OTHERS (PRE-CLINICAL AND RESEARCH)

TABLE 1 GLOBAL CLINICAL TRIAL MARKET HYPERLEPIDEMIA MARKET

Company Name Product Name

XX XX

XX XX

XX XX

XX XX

XX XX

XX XX

XX XX

Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews

TABLE 2 DISTRIBUTION OF PRODUCTS AND PROJECTS BY PHASE FOR HYPERLEPIDEMIA S MARKET

Phase Number of Projects

Preclinical/Research Projects XX

Clinical Development XX

Phase I XX

Phase II XX

Phase III XX

U.S. Filed/Approved but Not Yet Marketed XX

Total XX

Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews

TABLE 3 DISTRIBUTION OF PROJECTS BY THERAPEUTIC AREA AND PHASE FOR HYPERLEPIDEMIA MARKET

Therapeutic Area Preclinical/ Research Project

XX XX

XX XX

XX XX

XX XX

XX XX

Total Projects XX

Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews

TABLE 4 DISTRIBUTION OF PROJECTS BY SCIENTIFIC APPROACH AND PHASE HYPERLEPIDEMIA MARKET

Technology Preclinical/ Research Project

XX XX

XX XX

XX XX

XX XX

XX XX

Total Projects XX

Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews

FIGURE 1 TOP ENTITIES BASED ON R&D GLANCE FOR HYPERLEPIDEMIA MARKET

Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews

14 REIMBURSEMENT FRAMEWORK

15 OPPUTUNITY MAP ANALYSIS

16 VALUE CHAIN ANALYSIS

17 HEALTHCARE ECONOMY

17.1 HEALTHCARE EXPENDITURE

17.2 CAPITAL EXPENDITURE

17.3 CAPEX TRENDS

17.4 CAPEX ALLOCATION

17.5 FUNDING SOURCES

17.6 INDUSTRY BENCHMARKS

17.7 GDP RATION IN OVERALL GDP

17.8 HEALTHCARE SYSTEM STRUCTURE

17.9 GOVERNMENT POLICIES

17.1 ECONOMIC DEVELOPMENT

18 GLOBAL HYPERLEPIDEMIA MARKET, BY TYPE

18.1 OVERVIEW

18.2 FAMILIAL

18.3 ACQUIRED

19 GLOBAL HYPERLEPIDEMIA MARKET, BY TREATMENT

19.1 OVERVIEW

19.2 STATINS

19.2.1 BY TYPE

19.2.1.1. ATORVASTATIN

19.2.1.2. SIMVASTATIN

19.2.1.3. ROSUVASTATIN

19.2.1.4. PRAVASTATIN

19.2.1.5. LOVASTATIN

19.2.1.6. FLUVASTATIN

19.2.1.7. PITAVASTATIN

19.2.1.8. OTHERS

19.2.2 BY DRUG CLASS

19.2.2.1. BRANDED

19.2.2.1.1. LIPITOR

19.2.2.1.2. ZOCOR

19.2.2.1.3. OTHERS

19.2.2.2. GENERIC

19.3 BILE ACID SEQUESTRANTS

19.3.1 BY TYPE

19.3.1.1. HOLESTYRAMINE

19.3.1.2. COLESEVELAM

19.3.1.3. COLESTIPOL

19.3.1.4. OTHERS

19.3.2 BY DRUG CLASS

19.3.2.1. BRANDED

19.3.2.1.1. QUESTRAN

19.3.2.1.2. WELCHOL

19.3.2.1.3. OTHERS

19.3.2.2. GENERIC

19.4 FIBRIC ACID DERIVATIVES

19.4.1 BY TYPE

19.4.1.1. FENOFIBRATE

19.4.1.2. GEMFIBROZIL

19.4.1.3. OTHERS

19.4.2 BY DRUG CLASS

19.4.2.1. BRANDED

19.4.2.1.1. LOPID

19.4.2.1.2. TRILIPIX

19.4.2.1.3. OTHERS

19.4.2.2. GENERIC

19.5 PCSK9 INHIBITORS

19.5.1 BY TYPE

19.5.1.1. ALIROCUMAB

19.5.1.2. EVOLOCUMAB

19.5.1.3. OTHERS

19.5.2 BY DRUG CLASS

19.5.2.1. BRANDED

19.5.2.1.1. PRALUENT

19.5.2.1.2. OTHERS

19.5.2.2. GENERIC

19.6 COMBINATION

19.6.1 BY TYPE

19.6.1.1. EZETIMIBE/SIMVASTATIN

19.6.1.2. EZETIMIBE/ATORVASTATIN

19.6.1.3. EZETIMIBE/ROSUVASTATIN

19.6.1.4. AMLODIPINE/ATORVASTATIN

19.6.1.5. OTHERS

19.6.2 BY DRUG CLASS

19.6.2.1. BRANDED

19.6.2.2. GENERIC

19.7 CHOLESTEROL ABSORPTION INHIBITORS

19.7.1 BY DRUG CLASS

19.7.1.1. BRANDED

19.7.1.2. GENERIC

19.8 MISCELLANEOUS ANTIHYPERLIPIDEMIC AGENTS

19.8.1 BY DRUG CLASS

19.8.1.1. BRANDED

19.8.1.2. GENERIC

19.9 OTHERS

20 GLOBAL HYPERLEPIDEMIA MARKET, BY DRUGS CLASS

20.1 OVERVIEW

20.2 BRANDED

20.3 GENERICS

21 GLOBAL HYPERLEPIDEMIA MARKET, BY TYPE

21.1 OVERVIEW

21.2 MARKETED

21.3 PIPELINE

22 GLOBAL HYPERLEPIDEMIA MARKET, BY AGE GROUP

22.1 OVERVIEW

22.2 PEDIATRIC

22.3 ADULT

22.4 GERIATRIC

23 GLOBAL HYPERLEPIDEMIA MARKET, BY GENDER

23.1 OVERVIEW

23.2 MALE

23.3 FEMALE

24 GLOBAL HYPERLEPIDEMIA MARKET, BY PRESCRIPTION MODE

24.1 OVERVIEW

24.2 OVER THE COUNTER

24.3 PRESCRIPTION BASED

25 GLOBAL HYPERLEPIDEMIA MARKET, BY ROUTE OF ADMINISTRATION

25.1 OVERVIEW

25.2 ORAL

25.3 PARENTERAL

25.4 OTHERS

26 GLOBAL HYPERLEPIDIMIA MARKET, BY END USER

26.1 OVERVIEW

26.2 HOSPITALS

26.2.1 PUBLIC

26.2.2 PRIVATE

26.3 HOMECARE

26.4 AMBULATORY SURGICAL CENTERS

26.5 SPECIALITY CLINICS

26.6 OTHERS.

27 GLOBAL HYPERLEPIDIMIA MARKET, BY DISTRIBUTION CHANNEL

27.1 OVERVIEW

27.2 DIRECT TENDER

27.3 RETAILS SALES

27.3.1 HOPSITAL PHARMACY

27.3.2 RETAIL PHARMACY

27.3.3 ONLINE PHARMACY

27.4 OTHERS

28 GLOBAL HYPERLEPIDIMIA MARKET, BY GEOGRAPHY

28.1 GLOBAL HYPERLEPIDIMIA MARKET, (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)

28.1.1 NORTH AMERICA

28.1.1.1. U.S.

28.1.1.2. CANADA

28.1.1.3. MEXICO

28.1.2 EUROPE

28.1.2.1. GERMANY

28.1.2.2. FRANCE

28.1.2.3. U.K.

28.1.2.4. HUNGARY

28.1.2.5. LITHUANIA

28.1.2.6. AUSTRIA

28.1.2.7. IRELAND

28.1.2.8. NORWAY

28.1.2.9. POLAND

28.1.2.10. ITALY

28.1.2.11. SPAIN

28.1.2.12. RUSSIA

28.1.2.13. TURKEY

28.1.2.14. BELGIUM

28.1.2.15. NETHERLANDS

28.1.2.16. SWITZERLAND

28.1.2.17. REST OF EUROPE

28.1.3 ASIA-PACIFIC

28.1.3.1. JAPAN

28.1.3.2. CHINA

28.1.3.3. SOUTH KOREA

28.1.3.4. INDIA

28.1.3.5. AUSTRALIA

28.1.3.6. SINGAPORE

28.1.3.7. THAILAND

28.1.3.8. MALAYSIA

28.1.3.9. INDONESIA

28.1.3.10. PHILIPPINES

28.1.3.11. VIETNAM

28.1.3.12. REST OF ASIA-PACIFIC

28.1.4 SOUTH AMERICA

28.1.4.1. BRAZIL

28.1.4.2. ARGENTINA

28.1.4.3. PERU

28.1.4.4. REST OF SOUTH AMERICA

28.1.5 MIDDLE EAST AND AFRICA

28.1.5.1. SOUTH AFRICA

28.1.5.2. SAUDI ARABIA

28.1.5.3. UAE

28.1.5.4. EGYPT

28.1.5.5. KUWAIT

28.1.5.6. ISRAEL

28.1.5.7. REST OF MIDDLE EAST AND AFRICA

29 GLOBAL HYPERLEPIDIMIA MARKET, COMPANY LANDSCAPE

29.1 COMPANY SHARE ANALYSIS: GLOBAL

29.2 COMPANY SHARE ANALYSIS: NORTH AMERICA

29.3 COMPANY SHARE ANALYSIS: EUROPE

29.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC

29.5 MERGERS & ACQUISITIONS

29.6 NEW PRODUCT DEVELOPMENT & APPROVALS

29.7 EXPANSIONS

29.8 REGULATORY CHANGES

29.9 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS

30 GLOBAL HYPERLEPIDIMIA MARKET, SWOT AND DBMR ANALYSIS

31 GLOBAL HYPERLEPIDIMIA MARKET, COMPANY PROFILE

31.1 PFIZER INC.

31.1.1 COMPANY OVERVIEW

31.1.2 REVENUE ANALYSIS

31.1.3 GEOGRAPHIC PRESENCE

31.1.4 PRODUCT PORTFOLIO

31.1.5 RECENT DEVELOPMENTS

31.2 F. HOFFMANN-LA ROCHE AG

31.2.1 COMPANY OVERVIEW

31.2.2 REVENUE ANALYSIS

31.2.3 GEOGRAPHIC PRESENCE

31.2.4 PRODUCT PORTFOLIO

31.2.5 RECENT DEVELOPMENTS

31.3 SANOFI

31.3.1 COMPANY OVERVIEW

31.3.2 REVENUE ANALYSIS

31.3.3 GEOGRAPHIC PRESENCE

31.3.4 PRODUCT PORTFOLIO

31.3.5 RECENT DEVELOPMENTS

31.4 MYLAN N.V.

31.4.1 COMPANY OVERVIEW

31.4.2 REVENUE ANALYSIS

31.4.3 GEOGRAPHIC PRESENCE

31.4.4 PRODUCT PORTFOLIO

31.4.5 RECENT DEVELOPMENTS

31.5 GLAXOSMITHKLINE PLC

31.5.1 COMPANY OVERVIEW

31.5.2 REVENUE ANALYSIS

31.5.3 GEOGRAPHIC PRESENCE

31.5.4 PRODUCT PORTFOLIO

31.5.5 RECENT DEVELOPMENTS

31.6 B. BRAUN MEDICAL INC

31.6.1 COMPANY OVERVIEW

31.6.2 REVENUE ANALYSIS

31.6.3 GEOGRAPHIC PRESENCE

31.6.4 PRODUCT PORTFOLIO

31.6.5 RECENT DEVELOPMENTS

31.7 TARO PHARMACEUTICAL INDUSTRIES LTD.

31.7.1 COMPANY OVERVIEW

31.7.2 REVENUE ANALYSIS

31.7.3 GEOGRAPHIC PRESENCE

31.7.4 PRODUCT PORTFOLIO

31.7.5 RECENT DEVELOPMENTS

31.8 ASTRA ZENECA

31.8.1 COMPANY OVERVIEW

31.8.2 REVENUE ANALYSIS

31.8.3 GEOGRAPHIC PRESENCE

31.8.4 PRODUCT PORTFOLIO

31.8.5 RECENT DEVELOPMENTS

31.9 NOVARTIS AG

31.9.1 COMPANY OVERVIEW

31.9.2 REVENUE ANALYSIS

31.9.3 GEOGRAPHIC PRESENCE

31.9.4 PRODUCT PORTFOLIO

31.9.5 RECENT DEVELOPMENTS

31.1 MERCK & CO., INC.

31.10.1 COMPANY OVERVIEW

31.10.2 REVENUE ANALYSIS

31.10.3 GEOGRAPHIC PRESENCE

31.10.4 PRODUCT PORTFOLIO

31.10.5 RECENT DEVELOPMENTS

31.11 BRISTOL MYERS SQUIBB

31.11.1 COMPANY OVERVIEW

31.11.2 REVENUE ANALYSIS

31.11.3 GEOGRAPHIC PRESENCE

31.11.4 PRODUCT PORTFOLIO

31.11.5 RECENT DEVELOPMENTS

31.12 ELI LILLY AND COMPANY

31.12.1 COMPANY OVERVIEW

31.12.2 REVENUE ANALYSIS

31.12.3 GEOGRAPHIC PRESENCE

31.12.4 PRODUCT PORTFOLIO

31.12.5 RECENT DEVELOPMENTS

31.13 REGENERON PHARMACEUTICALS INC.

31.13.1 COMPANY OVERVIEW

31.13.2 REVENUE ANALYSIS

31.13.3 GEOGRAPHIC PRESENCE

31.13.4 PRODUCT PORTFOLIO

31.13.5 RECENT DEVELOPMENTS

31.14 AMGEN INC.

31.14.1 COMPANY OVERVIEW

31.14.2 REVENUE ANALYSIS

31.14.3 GEOGRAPHIC PRESENCE

31.14.4 PRODUCT PORTFOLIO

31.14.5 RECENT DEVELOPMENTS

31.15 DAIICHI SANKYO COMPANY, LIMITED.

31.15.1 COMPANY OVERVIEW

31.15.2 REVENUE ANALYSIS

31.15.3 GEOGRAPHIC PRESENCE

31.15.4 PRODUCT PORTFOLIO

31.15.5 RECENT DEVELOPMENTS

31.16 ALNYLAM PHARMACEUTICALS, INC.

31.16.1 COMPANY OVERVIEW

31.16.2 REVENUE ANALYSIS

31.16.3 GEOGRAPHIC PRESENCE

31.16.4 PRODUCT PORTFOLIO

31.16.5 RECENT DEVELOPMENTS

31.17 DR. REDDY'S LABORATORIES LTD.

31.17.1 COMPANY OVERVIEW

31.17.2 REVENUE ANALYSIS

31.17.3 GEOGRAPHIC PRESENCE

31.17.4 PRODUCT PORTFOLIO

31.17.5 RECENT DEVELOPMENTS

31.18 ESPERION THERAPEUTICS, INC.

31.18.1 COMPANY OVERVIEW

31.18.2 REVENUE ANALYSIS

31.18.3 GEOGRAPHIC PRESENCE

31.18.4 PRODUCT PORTFOLIO

31.18.5 RECENT DEVELOPMENTS

31.19 ABBVIE, INC.

31.19.1 COMPANY OVERVIEW

31.19.2 REVENUE ANALYSIS

31.19.3 GEOGRAPHIC PRESENCE

31.19.4 PRODUCT PORTFOLIO

31.19.5 RECENT DEVELOPMENTS

31.2 FORMAC PHARMACEUTICALS N.V.

31.20.1 COMPANY OVERVIEW

31.20.2 REVENUE ANALYSIS

31.20.3 GEOGRAPHIC PRESENCE

31.20.4 PRODUCT PORTFOLIO

31.20.5 RECENT DEVELOPMENTS

31.21 ZYDUS LIFESCIENCES

31.21.1 COMPANY OVERVIEW

31.21.2 REVENUE ANALYSIS

31.21.3 GEOGRAPHIC PRESENCE

31.21.4 PRODUCT PORTFOLIO

31.21.5 RECENT DEVELOPMENTS

NOTE: THE COMPANIES PROFILED IS NOT EXHAUSTIVE LIST AND IS AS PER OUR PREVIOUS CLIENT REQUIREMENT. WE PROFILE MORE THAN 100 COMPANIES IN OUR STUDY AND HENCE THE LIST OF COMPANIES CAN BE MODIFIED OR REPLACED ON REQUEST

32 RELATED REPORTS

33 CONCLUSION

34 QUESTIONNAIRE

35 ABOUT DATA BRIDGE MARKET RESEARCH